A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

NCT01791725 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Down Syndrome

Interventions

DRUG: ELND005
DRUG: Placebo

Sponsor

OPKO Health, Inc.

Collaborators

[object Object]